These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 3600936)
1. C5 measurement in membranoproliferative glomerulonephritis patients with C3 nephritic factor. Ohi H; Watanabe S; Seki M; Fujita T; Ohmori F; Hatano M Nephron; 1987; 46(2):217-8. PubMed ID: 3600936 [No Abstract] [Full Text] [Related]
2. [Direct detection C3bBb stabilizing activity in sera from hypocomplementaemic membranoproliferative glomerulonephritis (MPGN) and complement profiles of C3NeF positive cases]. Watanabe S; Ohi H; Seki M; Fujita T; Hatano M Nihon Jinzo Gakkai Shi; 1985 Oct; 27(10):1345-52. PubMed ID: 4094159 [No Abstract] [Full Text] [Related]
3. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis. Tanuma Y; Ohi H; Watanabe S; Seki M; Hatano M Clin Exp Immunol; 1989 Apr; 76(1):82-5. PubMed ID: 2736802 [TBL] [Abstract][Full Text] [Related]
4. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase. Ng YC; Peters DK Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695 [TBL] [Abstract][Full Text] [Related]
5. [Complement and nephritic activity in membranoproliferative glomerulonephritis]. Lévy M; Sich M; Habib R Arch Fr Pediatr; 1979 Nov; 36(9 Suppl):LXIV-LXXIV. PubMed ID: 539879 [TBL] [Abstract][Full Text] [Related]
6. A case of hypocomplementemic mesangiocapillary glomerulonephritis: appearance of C3 NeF and another factor. Seki M; Ohi H; Watanabe S; Kojima H; Fujita T; Hatano M Nihon Jinzo Gakkai Shi; 1987 May; 29(5):585-8. PubMed ID: 3656714 [No Abstract] [Full Text] [Related]
7. Modulation of complement by autoimmune antibodies isolated from sera of patients with membranoproliferative glomerulonephritis and systemic lupus erythematosus. Daha MR; Van Es LA Neth J Med; 1982; 25(7):202-7. PubMed ID: 6924073 [No Abstract] [Full Text] [Related]
8. [Complement activating factors in hypocomplementemic membranoproliferative glomerulonephritis (MPGN) patients' sera--comparison with C3NeF positive and negative cases]. Ohmori F; Ohi H; Seki M; Watanabe S; Hatano M Nihon Jinzo Gakkai Shi; 1987 Apr; 29(4):493-8. PubMed ID: 3656707 [No Abstract] [Full Text] [Related]
10. [Behavior of the nephritic factor and of circulating immune complexes in cryoglobulinemic glomerulonephritis]. Pertosa G; Vox E; Pastore A; Schena FP Minerva Nefrol; 1979; 26(3):251-5. PubMed ID: 262262 [No Abstract] [Full Text] [Related]
11. Detection of C3bBb-stabilizing activity (C3 nephritic factor) in the serum from patients with membranoproliferative glomerulonephritis. Ohi H; Watanabe S; Fujita T; Seki M; Hatano M J Immunol Methods; 1990 Jul; 131(1):71-6. PubMed ID: 2380570 [TBL] [Abstract][Full Text] [Related]
12. Does nephritic factor relate to the disease activity in hypocomplementemic membranoproliferative glomerulonephritis? Ohi H; Tanuma Y Nephron; 1992; 62(1):116. PubMed ID: 1436279 [No Abstract] [Full Text] [Related]
13. Idiopathic rapidly progressive glomerulonephritis with C3 nephritic factor and hypocomplementemia. Davis CA; McAdams AJ; Wyatt RJ; Forristal J; McEnery PT; West CD J Pediatr; 1979 Apr; 94(4):559-63. PubMed ID: 372512 [TBL] [Abstract][Full Text] [Related]
14. Renal transplantation for patients with type I and type II membranoproliferative glomerulonephritis: serial complement and nephritic factor measurements and the problem of recurrence of disease. Curtis JJ; Wyatt RJ; Bhathena D; Lucas BA; Holland NH; Luke RG Am J Med; 1979 Feb; 66(2):216-25. PubMed ID: 371395 [TBL] [Abstract][Full Text] [Related]
15. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III. Clardy CW; Forristal J; Strife CF; West CD Clin Immunol Immunopathol; 1989 Mar; 50(3):333-47. PubMed ID: 2917424 [TBL] [Abstract][Full Text] [Related]
16. Test for C3 nephritic factor activity by immunofixation electrophoresis. Koch FJ; Jenis EH; Valeski JE Am J Clin Pathol; 1981 Jul; 76(1):63-7. PubMed ID: 6789671 [TBL] [Abstract][Full Text] [Related]
17. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro. Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694 [TBL] [Abstract][Full Text] [Related]
19. [Mechanisms of action and clinical importance of C3-nephritic-factor (author's transl)]. Lanzer G; Pogglitsch H; Tilz GP Acta Med Austriaca; 1981; 8(1):7-13. PubMed ID: 6908995 [TBL] [Abstract][Full Text] [Related]
20. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis. Hiramatsu M; Balow JE; Tsokos GC J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]